Corbus Pharmaceuticals (CRBP) to Release Quarterly Earnings on Thursday

Corbus Pharmaceuticals (NASDAQ:CRBP) is scheduled to announce its earnings results before the market opens on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.45). Corbus Pharmaceuticals had a negative return on equity of 166.99% and a negative net margin of 1,219.36%. The business had revenue of $1.89 million for the quarter, compared to the consensus estimate of $20.97 million. On average, analysts expect Corbus Pharmaceuticals to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

NASDAQ CRBP traded up $0.13 during trading hours on Tuesday, reaching $5.66. 16,344 shares of the company’s stock were exchanged, compared to its average volume of 492,999. The business’s 50-day moving average price is $6.53. Corbus Pharmaceuticals has a one year low of $4.50 and a one year high of $9.11. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.78 and a quick ratio of 1.78. The firm has a market capitalization of $360.98 million, a P/E ratio of -5.71 and a beta of 1.84.

A number of analysts recently issued reports on CRBP shares. HC Wainwright set a $24.00 target price on Corbus Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, June 24th. Zacks Investment Research raised Corbus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.75 target price for the company in a research note on Thursday, July 25th. ValuEngine cut Corbus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday. Finally, BidaskClub cut Corbus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, July 23rd. One analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. Corbus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $23.47.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase 3 clinical trial for the treatment of systemic sclerosis and dermatomyositis, and in Phase 2 clinical trial to treat systemic lupus erythematosus and cystic fibrosis.

Featured Article: How mutual funds make money

Earnings History for Corbus Pharmaceuticals (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.